Why Nasdaq-100 Inverse ETF SQQQ Is Down This Week

ProShares UltraPro Short QQQ ETF (NASDAQ: SQQQ) shares are trading sharply lower by some 3.72% to $29.68 on a week-to-date basis Friday morning. SQQQ is a popular, 3x-leveraged inverse ETF that tracks the Nasdaq-100.

ProShares UltraPro Short QQQ ETF (NASDAQ:SQQQ) shares are trading sharply lower by some 3.72% to $29.68 on a week-to-date basis Friday morning. SQQQ is a popular, 3x-leveraged inverse ETF that tracks the Nasdaq-100.

Major indices are higher for the week following strong quarterly results from megacap tech companies, including Microsoft Corporation (NASDAQ:MSFT) and Meta Platforms Inc (NASDAQ:META), adding to positive market sentiment for the week. Additionally, initial jobless claims came in below estimates.

What Else is Going On In The Broader Market?

The SPDR S&P 500 ETF and other major indicies are otherwise experiencing weakness Friday morning after the Bureau of Economic Analysis reported a 4.2% increase in the personal consumption expenditures price index in the month of March, suggesting the Federal Reserve still has a long way to go in its battle against inflation…Read More

According to data from Benzinga Pro, SQQQ has a 52-week high of $69.55 and a 52-week low of $29.18.

Total
0
Shares
Related Posts
Read More

GSK Announced FDA Accepted New Drug Application for Momelotinib for the Treatment of Myelofibrosis

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action that may address the significant unmet medical needs of myelofibrosis patients with anaemia. The US FDA has assigned a Prescription Drug User Fee Act action date of 16 June 2023.

GSK